Cspc Pharmaceutical
Cspc Pharmaceutical Group Limited, commonly referred to as Cspc, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1997, the company has made significant strides in research and development, focusing on innovative drug formulations and high-quality generic medicines. With a strong presence in both domestic and international markets, Cspc operates extensively across Asia, Europe, and North America. Cspc's core offerings include a diverse range of prescription drugs, over-the-counter products, and active pharmaceutical ingredients (APIs). The company is particularly noted for its advancements in oncology, cardiovascular, and central nervous system therapies, setting it apart through its commitment to quality and efficacy. Recognised for its robust market position, Cspc has achieved numerous accolades, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Cspc Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cspc Pharmaceutical's score of 22 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cspc Pharmaceutical's reported carbon emissions
In 2023, Cspc Pharmaceutical reported total carbon emissions of approximately 1,081,261,000 kg CO2e, comprising 663,224,000 kg CO2e from Scope 1 and 418,037,000 kg CO2e from Scope 2 emissions. This marks a notable increase from 2022, where total emissions were about 1,137,042,000 kg CO2e, with Scope 1 emissions at 564,429,000 kg CO2e and Scope 2 at 572,613,000 kg CO2e. Over the years, Cspc Pharmaceutical has shown fluctuations in its emissions. In 2021, the total emissions were approximately 1,181,000,000 kg CO2e, with Scope 1 at 580,318,000 kg CO2e and Scope 2 at 600,682,000 kg CO2e. The company reported a decrease in total emissions from 2019, which were about 925,863,140 kg CO2e, with Scope 1 emissions at 231,562,000 kg CO2e and Scope 2 at 892,873,000 kg CO2e. Despite these figures, Cspc Pharmaceutical has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company operates within an industry context that increasingly prioritises sustainability and carbon footprint reduction, yet it currently lacks formal commitments to align with these trends.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 231,562,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 892,873,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cspc Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
